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The aim of the study was to investigate the impact of primary tumor locoregional treatment (surgery or/and radiotherapy) on overall 
survival in patients with primary metastatic breast cancer (PMBC). Materials and Methods: This retrospective study included 295 wo men 
aged from 23 to 76 years with PMBC. Among the 295 patients, the effect of locoregional treatment of primary tumor on survival outcomes 
was evaluated in 177 women with distant metastases at diagnosis of breast cancer. 35 patient received breast surgery (group 1), 95 patients 
with PMBC — radiotherapy (group 2) and 47 patients — combination of breast surgery and radiation (group 3). The remaining 118 pa-
tients didn’t receive surgery or/and radiotherapy (group 4). All patients received systemic cytotoxic chemotherapy. Results: The groups 
of patients with PMBC did not differ significantly by age, menstrual function, ER status, Her2 receptor status, site of metastasis and 
number of metastatic lesions. 2- and 5-year overall survival in patients of group 1 was 54 and 32%, group 2 — 47 and 8%, group 3 — 
73 and 18%, whereas in patients from group 4 — 26 and 9%, respectively. The median survival of patients who underwent surgery was 
36 months, patients with PMBC who received radiotherapy — 24 months, patients who obtained combination of breast surgery and ra-
diation — 30 months vs 18 months in patients who did not undergo primary tumor locoregional treatment. Conclusions: The results of this 
study showed a favourable effect of locoregional treatment in patients with PMBC.
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Breast cancer (BC) is one of the most com-
mon cancers among women worldwide. In 2012, 
BC incidence was 43.3 per 100,000 female population, 
1,676,633 new cases and 521,907 deaths from this 
disease were registered worldwide, which accounted 
for 25.2% of cases and 14.7% of deaths among all 
cancers in women [1]. In Europe and United States 
of America 5–10% of patients of BC are diagnosed with 
primary metastatic disease and median survival ranges 
from 18 to 24 months [2]. According to the National 
Cancer Registry of Ukraine in 2014 7.0% of patients 
were diagnosed with primary metastatic breast cancer 
(PMBC) [3]. Treatment of metastatic BC is palliative 
and symptomatic and must prolongate survival, control 
tumor burden, reduce cancer-related symptoms and 
improve quality of life. In recent years, the approach 
for the management of PMBC has been revised.
The value of the locoregional treatment (LRT) of the 
primary tumor and its impact on distant metastasis and 
survival is controversial. Currently, surgical treatment 
in this group of patients is used only to prevent and/
or treat local complications. However, results of many 
retrospective population-based trials demonstrated 
that an intensified multidisciplinary approach combin-
ing systemic therapies with surgery [4, 5], radiation, 
and regional chemotherapy may not only prevent local 
complications, but prolong survival of such patients 
similarly to the benefits observed in renal, colorectal, 
ovarian and gastric carcinoma [6–10]. The aim of this 
study was to investigate the impact of primary tumor 
LRT (surgery or/and radiotherapy) on overall survival 
(OS) in patients with PMBC.
MATERIALS AND METHODS
The study included 295 women with PMBC aged 
from 23 to 76 years (median age 55 ± 11 years) who 
received treatment at the clinic of the Department 
of Oncology of the O.O. Bogomolets National Medical 
University based at the Kyiv Municipal Clinical On-
cological Center from 2004 to 2006. All women with 
histologically proven BC and whose distant metas-
tases are discovered at their first admittance were 
included in this study (in total, 295 patients). The 
diagnosis was defined according to the International 
TNM-classification (6th edition 2002). Patients with iso-
lated involvement of ipsilateral supraclavicular lymph 
nodes or contralateral lymph nodes metastases were 
excluded from this study.
Among the 295 patients with PMBC, the effect 
of LRT of primary tumor on survival outcomes was 
evaluated in 177 women with distant metastases 
at diagnosis of BC. 35 patient received breast surgery 
(group 1), 95 patients — radiotherapy (group 2), and 
47 patients — combination of breast surgery and radio-
therapy (group 3). The remaining 118 patients didn’t re-
ceive surgery or/and radiotherapy (group 4). The study 
was approved by the Local Medical Ethics Committee. 
All patients gave their written informed consent be-
fore inclusion in this study. Patients from group 2 and 
3 received radiation therapy delivered by a five-field 
technique. Field for conventional radiation treatment 
of the breast/chest wall: medial and lateral tangen-
tial fields of the whole breast are irradiated. Upper 
bound — lower edge of the clavicular head, i.e. lower 
edge of the first rib, lower bound — 1–2 cm inferior 
to the breast skin folds, medial margin — body midline 
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and lateral margin — middle axillary line or posterior 
axillary line. The target dose was a median absorbed 
dose of 50 Gy in 25 fractions in 5 weeks. All patients 
received systemic cytotoxic chemotherapy.
Statistical analysis. Statistical significance of dif-
ferences between the treatment group was evaluated 
by ANOVA and analysis of contingency tables 2xK type. 
Differences were considered statistically significant 
at a significance level (p) lower than 0.05. Survival was 
analyzed using the Kaplan — Meier method comparing 
the elapsed time in months from diagnosis (start of the 
study), to death (critical event) due to BC progression, 
but not other causes. All statistical calculations were 
performed using Statistica 6.0 program.
RESULTS
The Table shows the clinical baseline characte-
ristics of the patients. The study groups did not differ 
significantly by age, menstrual function, estrogen 
receptor (ER) status, Her2/neu receptor status, site 
of metastasis and number of metastatic lesions, in-
dicating the equal distribution of patients in groups 
on the above criteria.
Table. Clinicopathological characteristics of BC patients
Characteristic Total
Group p  
value1 2 3 4No. % N (%) N (%) N (%) No(%)
Menstrual status > 0.05
Premenopause 101 34 12 (34) 38 (40) 18 (38) 33 (28)
Postmeno-
pause
194 66 23 (66) 57 (60) 29 (62) 85 (72)
Age at diagnosis, years > 0.05
≤ 40 63 21 8 (23) 19 (20) 12 (25,5) 24 (20)
41–69 192 65 21 (60) 56 (59) 31 (66) 84 (71)
≥ 70 40 14 6 (17) 20 (21) 4 (8,5) 10 (9)
Number of metastatic lesions > 0.05
≤ 2 163 55 19 (54) 57 (60) 29 (62) 58 (49)
> 2 132 45 16 (46) 38 (40) 18 (38) 60 (51)
Site of metastasis > 0.05
Visceral 41 14 5 (14) 8 (8.5) 8 (17) 20 (17)
Bone only 61 21 7 (20) 25 (26.5) 11 (23) 18 (15)
Bone + visceral 177 60 23 (66) 61 (64) 28 (60) 65 (55)
Brain 16 5 0 1 (1) 0 15 (13)
Hormone receptor status > 0.05
ER positive 201 68 24 (69) 71 (75) 30 (64) 76 (64)
ER negative 94 32 11 (31) 24 (25) 17 (36) 42 (36)
PR positive 192 65 21 (60) 67 (70.5) 33 (70) 71 (60) > 0.05
PR negative 103 35 14 (40) 28 (29.5) 14 (30) 47 (40)
Her2/neu expression > 0.05
Positive 86 29 10 (29) 22 (23) 13 (28) 41 (35)
Negative 209 71 25 (71) 73 (77) 34 (72) 77 (65)
The median follow-up time of the whole population 
was 28 months (in a range 3–75 months). The Figure 
shows survival curves of PMBC patients from study 
groups according to treatment type.
2- and 5-year OS in patients of group 1 was 54 and 
32%, group 2 — 47 and 8%, group 3 — 73 and 18%, 
whereas those of patients of groups 4 were 26 and 
9%, respectively. The median survival for patients 
who underwent surgery was 36 months, patients who 
received radiotherapy — 24 months, patients who 
were treated by combination of breast surgery and 
radiation was 30 months vs 18 months in patients who 
did not receive primary tumor LRT (surgery or/and 
radiotherapy). That shows the positive impact of LRT 
on the prognosis of patients with stage IV BC.
DISCUSSION
The PMBC should be considered as a terminal grade 
of chronic disease, and systemic cytotoxic therapy 
should be included to treatment protocols of stage 
IV BC. The effects of endocrine, cytotoxic, targeted, 
or combination treatments in PMBC have been stud-
ied in many prospective clinical trials. Despite initial 
response, mostly such patients develop progressive 
disease within 12–24 months, the median survival 
of endocrine nonresponsive or resistant metastatic 
BC is 18–24 months, and less than 5% of patients live 
5 years. If a response is observed at all sites, continua-
tion of the effective systemic therapy is reasonable [11].
The role of locoregional therapy in patients with 
metastatic BC is largely unexplored. There were none 
prospective randomized trials dealing with this topic. 
In patients whose tumor is well controlled at distant 
sites but is progressing locally, local surgery and/or ra-
diotherapy should be discussed. Traditionally, patients 
with PMBC have limited local treatments and palliative 
management of uncontrolled local and/or regional dis-
ease (in a form of so-called “toilette mastectomy” or low-
dose radiotherapy) [2]. There are still open questions 
regarding the type of breast surgery and indication for 
radiotherapy. The biological role for removing the primary 
tumor in a case of disease dissemination is debatable. 
Several potential advantages have been proposed. By re-
moving the primary tumor, one of the sources of further 
metastatic spread is eradicated; this risk of reseeding 
is more relevant with the current improvements in sys-
temic treatments. Data from animal studies suggest that 
removal of tumor bulk may restore immunocompetence 
because the primary tumor seems to modulate the 
immune system through release of immunosuppres-
sive factors. A reduction in the number of cancer cells 
may also lead to increased efficacy of systemic therapy 
by decreasing the risk of emergence of chemoresistant 
cells and by removal of necrotic tumor tissue poorly ac-
cessible to drugs. Debulking surgery has been proven 
clinically effective in other common solid tumors, such 
as ovarian, colorectal, gastric, renal cancers, and malig-
nant melanoma [11].
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Figure. OS in patients with PMBC analyzed using the Kaplan — 
Meier method
In PMBC, radiotherapy of the primary tumor 
is frequently combined with breast surgery, making 
it difficult to discriminate between effects of surgery 
or radiotherapy alone. In terms of locoregional con-
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trol, primary radiotherapy seems to be as effective 
as surgery. In a retrospective study by Bourgier et al. 
[12], radiation alone was compared with surgery of the 
primary tumor plus radiotherapy. The 3-year OS rates 
were 39 and 57%, respectively. Le Scodan et al. [13] 
presented a retrospective review of patients with 
PMBC at the Renee Cancer Center in France. LRT was 
applied to 320 patients: 249 (78%) were treated with 
radiotherapy alone, 41 (13%) underwent surgery plus 
radiation, and 30 (9%) were treated only with surgery. 
The 3-year OS rates were 43.2% in the group with LRT 
and 26.7% in the group without LRT. In our study, 2- and 
5-year OS in patients who gotten radiotherapy were 47% 
and 8%, respectively, and 73 and 18% in patients who 
received combination of breast surgery and radiation.
Our study showed the LRT of the intact primary 
tumor in PMBC patients improved median survival time 
and OS. The pivotal question, which selected patients 
would benefit from breast surgery concerning survival, 
cannot be answered by the existing retrospective 
data by the current meta-analysis. The optimal point 
of time and the decision for or against breast surgery 
and radiation depending on the response to systemic 
therapy remain unclear. Nevertheless, results of mul-
tivariable analyses controlling these confounding 
factors, consistently suggest a survival benefit for 
optimal LRT of the primary tumor. Some questions 
still remain unsolved, including which patients could 
benefit most from LRT and what is its optimal timing 
and the best systemic cytotoxic treatment regime for 
these selected patients. Prospective randomization 
studies are needed to validate these findings. While 
waiting for data from these studies, LRT for breast 
primary tumor can be considered as a relatively inex-
pensive and low morbidity treatment, which can offer 
a rapid local control and has a potential for impoving 
patient’s survival.
CONCLUSIONS
The optimal management of stage IV BC is unknown, 
and thus there is no consensus about the value of sur-
gery in the management of this population. A clinician 
and a patient may consider surgical resection of the 
primary tumor in this setting for multiple reasons. LRT 
of the primary tumor in metastatic BC patients could ex-
ert two major effects: the effect of surgery on OS and its 
effect on local disease control. In patients whose tumor 
is well controlled at distant sites but progressing locally, 
local surgery and/or radiotherapy should be discussed.
The results of this study showed the positive impact 
of LRT on the prognosis of patients with PMBC. How-
ever, further research should be aimed on establishing 
criteria for selecting patients with PMBC for primary 
tumor LRT (surgery or/and radiotherapy).
This research was presented in part at the Advanced 
Breast Cancer Third International Consensus Confe-
rence, November 5–7, 2015, Lisbon, Portugal.
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